Study highlights major hurdles for multinational clinical trials in Europe

Quantifying ethical, administrative, regulatory, and logistical (EARL) hurdles in multinational randomized clinical trials

2025-07-02

(Press-News.org) Study Highlights Major Hurdles for Multinational Clinical Trials in Europe

A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on significant ethical, administrative, regulatory, and logistical (EARL) hurdles in delivering multinational randomized clinical trials. The research was the first to comprehensively quantify these barriers for an international platform trial and emphasizes the need for urgent improvements, particularly in preparing for future public health crises.

Randomized controlled trials provide the highest level of evidence to inform medical practice. Yet, delivering such trials presents significant operational challenges and is becoming increasingly difficult. One of the many challenges of conducting high-quality, large-scale clinical research is ensuring compliance with all necessary ethical, administrative, regulatory, and logistical (EARL) requirements. In the event of severe infectious disease outbreaks requiring rapid action, EARL requirements and cross-country coordination make it challenging to implement clinical studies. The COVID-19 pandemic has demonstrated that there is wide variation in how countries approached clinical research in a public health emergency. However, the differences in timelines between countries have not been comprehensively quantified.

Comparing timelines

In this study, researchers quantified the timelines for EARL procedures, comparing different European countries. They used data from the Randomized Embedded Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP), which spanned both the pre-pandemic (2016-2020) and pandemic (2020-2023) periods. REMAP-CAP, an international clinical trial with an innovative adaptive platform design, was designed to test multiple drugs for the treatment of pneumonia, including COVID-19, which allowed for the comparison of a large number of submissions. The new analysis, published this week in JAMA Network Open, covered 257 fully signed contracts with study sites in 19 European countries and focused on three key metrics: time to complete site contracts, time to regulatory and ethical approval (TTA), and time to first patient enrollment (FPI).

Differences between countries

The results showed that the UK achieved dramatic gains in efficiency during the pandemic, with median contract completion time dropping by 97 percent: from 196 days pre-pandemic to just 5 days during the pandemic. In contrast, non-UK countries in Europe saw only an 18 percent decrease, with median times dropping from 224 to 183 days. The study also revealed stark differences in the time to ethical and regulatory approvals. Median TTA in the UK during the pandemic was 8 days, compared to 115 days in non-UK countries. Time from approval to first patient enrollment was, on average, three months faster in the UK (26 days versus 116 days).

“These findings highlight the striking differences in research infrastructure and interpretation of regulatory guidelines across Europe” said epidemiologist Denise van Hout, MD, PhD (Research Program Epidemiology of Infectious Diseases, UMC Utrecht), first author of the manuscript. “For researchers, it is clear that EARL processes in Europe can be a major bottleneck to trial initiation and execution, slowing down patient access to potentially life-saving therapies. But addressing these challenges requires proactive efforts, also from researchers themselves.”

Consistent, transparent processes

The researchers also noted that while the UK benefited from its established research networks and emergency trial frameworks, other countries continued to face considerable challenges. These differences underscore the need for harmonization of EARL procedures across countries to reduce delays and maximize the impact of collaborative trials.

“For researchers planning or conducting multinational studies, it is vital to acknowledge how preparation and engagement with ethical processes can contribute early on.” Van Hout emphasized. “Researchers, policymakers, legal experts, and regulators must collaborate to develop consistent, transparent processes that prioritize trial delivery without compromising safety and ethics. This also includes more efficient contracting. Greater collaboration and streamlining EARL procedures are essential to ensure that patients across Europe can benefit from innovative research, especially during future pandemics.”

Reference

Van Hout D, Mouncey P, Harrison D, Bonten M, Derde L, and the REMAP-CAP European Regional Investigators. Hurdles for the Delivery of Multinational Randomized Clinical Trials. JAMA Network Open, July 2, 2025.

END

ELSE PRESS RELEASES FROM THIS DATE:

Chemistry breakthrough has potential to make more effective cancer drugs with less harmful side effects

2025-07-02

Chemists have discovered for the first time a unique way to control and modify a type of compound widely used in medicines, including a drug used to treat breast cancer. The research, led by the University of Bristol and published today in the journal Nature, also found a new mechanism associated with the chemical reaction which enables the shape of the compound to be flipped from being right-handed to left-handed by simply adding a common agent in the chemical reaction. Study lead author Varinder Aggarwal, Professor of Synthetic Chemistry at the University of Bristol, said: “The findings change our understanding of the fundamental chemistry of this group of organic ...

Researchers identify new protein target to control chronic inflammation

2025-07-02

Chronic inflammation occurs when the immune system is stuck in attack-mode, sending cell after cell to defend and repair the body for months or even years. Diseases associated with chronic inflammation, like arthritis or cancer or autoimmune disorders, weigh heavily on human health—and experts anticipate their incidence is on the rise. A new study by investigators from Mass General Brigham identified a protein called WSTF that could be targeted to block chronic inflammation. Crucially, this strategy would not ...

Increasing contingency management incentives will help more patients recover from addiction

2025-07-02

Early recovery from drug addiction to opioids and stimulants is physically and mentally demanding, and a long road to recovery. “During the early stages of addiction recovery there is typically not much that is positive for patients,” shares behavioral health counselor Carla J. Rash, Ph.D. of UConn School of Medicine. “But Contingency Management is an effective, behavioral tool bringing some early-on positivity to a patient’s addiction recovery treatment plan until the positive benefits of their medication and body’s natural recovery kicks-in.” Rash adds, “Essentially, ...

Changes in the blood could protect against Alzheimer’s disease

2025-07-02

A study published in Cell Stem Cell reveals that some mutations in blood stem cells might help protect against late-onset Alzheimer’s disease. A team led by researchers at Baylor College of Medicine discovered that both a mouse model and people carrying blood stem cells with mutations in the gene TET2, but not in the gene DNMT3A, had a lower risk for developing Alzheimer’s disease. Their study proposes a mechanism that can protect against the disease and opens new avenues for potential strategies to control the emergence ...

New tool allows researchers to track assembly of cells’ protein-making machines

2025-07-02

Proteins are the infinitely varied chemicals that make cells work, and science has a pretty good idea how they are made. But a critical aspect underlying the machinery of protein manufacture has long been hidden inside a blobby cellular structure called the nucleolus. Now, a team of Princeton engineers have developed a technique to peer inside the nucleolus and reveal this hidden system of creation. Previous methods required researchers to break open the cell and destroy most of its structures, resulting in minimal access to the blob’s inner workings. By tracking the movement of RNA molecules inside the nucleolus using advanced imaging and genomics techniques, ...

New genetic marker linked to improved survival with immunotherapy in ovarian and other cancers

2025-07-02

Ovarian clear cell carcinoma is difficult to treat, and treatment options are limited Patients with specific PPP2R1A mutations in their tumors survived significantly longer after immunotherapy treatment Targeting PPP2R1A may improve responses even further according to laboratory studies PPP2R1A is an important predictive biomarker and possible treatment target for multiple cancer types, study found HOUSTON, JULY 2, 2025 ― Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found ...

AI that thinks like us – and could help explain how we think

2025-07-02

Researchers at Helmholtz Munich have developed an artificial intelligence model that can simulate human behavior with remarkable accuracy. The language model, called Centaur, was trained on more than ten million decisions from psychological experiments – and makes decisions in ways that closely resemble those of real people. This opens new avenues for understanding human cognition and improving psychological theories. For decades, psychology has aspired to explain the full complexity of human thought. Yet traditional models could either offer a transparent ...

The imitation game – why are some species better at fooling predators than others?

2025-07-02

Experts from the University of Nottingham have created life-size 3D-printed insect models to explore how some species trick predators into thinking they're more dangerous than they really are — and avoid being eaten as a result. In the new study, published in Nature, a team of experts, led by Dr Tom Reader and Dr Christopher Taylor in the School of Life Sciences, used 3D printed models to investigate Batesian mimicry – a phenomenon where a harmless species evolves to resemble a harmful species, fooling ...

Gas leakage triggers wound healing in plants

2025-07-02

Scientists at the University of Helsinki discovered how plants heal their protective outer layer, the periderm. The diffusion of ethylene and oxygen through a wound triggers repair – a finding with potential implications for crop resilience, and food preservation. All living organisms rely on protective barrier tissues to shield them from the environment. In plants, the periderm which forms the tough outer cork layer plays this role, helping to prevent water loss and block harmful microbes, for example in potato skin and tree bark. But what happens ...

Forging a novel therapeutic path for patients with Rett Syndrome using AI

2025-07-02

Forging a novel therapeutic path for patients with Rett Syndrome using AI AI-enabled drug discovery approach identified potentially game-changing treatment which has been advanced from the lab bench to an FDA Orphan Drug Designation in record time By Benjamin Boettner (BOSTON) — Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are born with it and much fewer boys. It is caused by mutations in the MeCP2 gene on the X chromosome, leading to a spectrum of cognitive and physical impairments, including ...